Patent details
EP2501373 Title: USE OF ALPHA 2 ADRENERGIC RECEPTOR AGONISTS FOR TREATING OR PREVENTING PSORIASIS
Basic Information
- Publication number:
- EP2501373
- PCT Application Number:
- PCT/US/2010/057184
- Type:
- European Patent Granted for LU
- Legal Status:
- Lapsed
- Application number:
- EP107799066
- PCT Publication Number:
- WO/2011/075267
- First applicant's nationality:
- Translation Language:
- EPO Publication Language:
- English
- English Title of Invention:
- USE OF ALPHA 2 ADRENERGIC RECEPTOR AGONISTS FOR TREATING OR PREVENTING PSORIASIS
- French Title of Invention:
- UTILISATION D'AGONISTES DU RÉCEPTEUR ALPHA 2 ADRÉNERGIQUE POUR TRAITER OU PRÉVENIR LE PSORIASIS
- German Title of Invention:
- VERWENDUNG VON ALPHA-2 ADRENERGISCHEN REZEPTORAGONISTEN ZUR BEHANDLUNG ODER PRÄVENTION VON SCHUPPENFLECHTE
- SPC Number:
Dates
- Filing date:
- 18/11/2010
- Grant date:
- 25/02/2015
- EP Publication Date:
- 25/02/2015
- PCT Publication Date:
- 23/06/2011
- Claims Translation Received Date:
- Translations Received Date (B1 EP Publication):
- Translations Received Date (B2 EP Publication):
- Translations Received Date (B3 EP Publication):
- Publication date:
- 26/09/2012
- EP B1 Publication Date:
- 25/02/2015
- EP B2 Publication Date:
- EP B3 Publication Date:
- Lapsed date:
- 18/11/2015
- Expiration date:
- 18/11/2030
- Renunciation date:
- Revocation date:
- Annulment date:
Owner
- From:
- 18/11/2010
- Name:
- Galderma Laboratories LP
- Address:
- 14501 North Freeway, Fort Worth, TX 76177, United States (US)
Inventor
- Name:
- DEJOVIN Jack, A.
- Address:
- United States (US)
Priority
- Priority Number:
- 621942
- Priority Date:
- 19/11/2009
- Priority Country:
- United States (US)
Classification
- Main IPC Class:
- A61K 31/135;
Annual Fees
- Annual Fee Due Date:
- Annual Fee Number:
- Expected Payer:
- Last Annual Fee Payment Date:
- Last Annual Fee Paid Number:
- Payer:
| Filing date | Document type | Number of pages |
|---|